Market Closed -
Nasdaq
04:30:01 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
5.46
USD
|
-0.91%
|
|
-14.69%
|
-26.22%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
38.74
|
18.77
|
7.71
|
Enterprise Value (EV)
1 |
-14.22
|
-13.45
|
-8.54
|
P/E ratio
|
-8.47
x
|
-1.16
x
|
-0.57
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,572,194,728
x
|
38,574,720
x
|
-
|
EV / Revenue
|
-944,383,814
x
|
-27,645,426
x
|
-
|
EV / EBITDA
|
3,156,725
x
|
909,847
x
|
557,033
x
|
EV / FCF
|
9,450,797
x
|
1,350,459
x
|
1,166,983
x
|
FCF Yield
|
0%
|
0%
|
0%
|
Price to Book
|
0.79
x
|
0.39
x
|
0.33
x
|
Nbr of stocks (in thousands)
|
1,094
|
1,462
|
1,042
|
Reference price
2 |
35.40
|
12.83
|
7.400
|
Announcement Date
|
3/30/22
|
3/30/23
|
3/29/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
0.0151
|
0.4866
|
-
|
EBITDA
|
-
|
-4.506
|
-14.78
|
-15.33
|
EBIT
1 |
-0.041
|
-4.507
|
-14.82
|
-15.98
|
Operating Margin
|
-
|
-29,925.73%
|
-3,045.12%
|
-
|
Earnings before Tax (EBT)
1 |
-0.041
|
-2.174
|
-13.94
|
-15.51
|
Net income
1 |
-0.041
|
-2.174
|
-13.94
|
-15.96
|
Net margin
|
-
|
-14,430.49%
|
-2,864.29%
|
-
|
EPS
|
-
|
-4.178
|
-11.04
|
-13.01
|
Free Cash Flow
|
-
|
-1.505
|
-9.96
|
-7.318
|
FCF margin
|
-
|
-9,992.64%
|
-2,047.11%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/13/21
|
3/30/22
|
3/30/23
|
3/29/24
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
---|
Net sales
1 |
0.0151
|
0.0137
|
0.0136
|
0.2186
|
0.2407
|
-
|
-
|
EBITDA
|
-1.96
|
-2.4
|
-2.51
|
-
|
-
|
-
|
-
|
EBIT
|
-1.956
|
-
|
-3.08
|
-
|
-
|
-
|
-
|
Operating Margin
|
-12,989.77%
|
-
|
-22,681.08%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/16/22
|
8/15/22
|
11/14/22
|
3/30/23
|
5/12/23
|
8/11/23
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.24
|
53
|
32.2
|
16.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-1.51
|
-9.96
|
-7.32
|
ROE (net income / shareholders' equity)
|
-
|
-8.41%
|
-29.7%
|
-47.1%
|
ROA (Net income/ Total Assets)
|
-
|
-10.5%
|
-18.8%
|
-28%
|
Assets
1 |
-
|
20.67
|
74.12
|
56.97
|
Book Value Per Share
2 |
0.6500
|
44.70
|
32.60
|
22.50
|
Cash Flow per Share
2 |
0.6500
|
46.00
|
25.50
|
15.70
|
Capex
|
-
|
0.02
|
0.37
|
0.03
|
Capex / Sales
|
-
|
142.76%
|
77.05%
|
-
|
Announcement Date
|
4/13/21
|
3/30/22
|
3/30/23
|
3/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -26.22% | 5.7M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|